CTLA4 and cancer: Recent years have seen profound development with immune checkpoint blockade therapy (monoclonal antibodies against programmed death protein 1; PD1 and cytotoxic T-lymphocyte associated protein 4; CTLA4) (14–17) and chimeric antigen receptor T cell (CAR- T) therapy proving themselves to be powerful anti- cancer therapeutics (18, 19).